BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

...Micklus, Senior Biopharma Analyst AbbVie Inc. Allergan plc Takeda Pharmaceutical Co. Ltd. Shire plc Bristol Myers Squibb Co. Celgene Corp. Johnson & Johnson Actelion Ltd. Gilead...
BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

...too, is a veteran of the rare metabolic disease space, having worked on programs at Actelion Ltd....
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...company Arvelle Therapeutics GmbH appointed Otto Schwarz as chairman. He was EVP and COO of Actelion Ltd....
BioCentury | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

...arterial hypertension (PAH) drugs that Johnson & Johnson (NYSE:JNJ) gained through its 2017 acquisition of Actelion Ltd....
BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

...a mAb fragment that binds VEGF and neutralizes it. Actelion pulls regulatory submissions for Opsumit Actelion Ltd....
...data will be needed to evaluate an sNDA for the endothelin receptor antagonist in CTEPH. Actelion...
...foam (FMX103) Elunate, fruquintinib (HMPL-013) RGX-314 Opsumit, macitentan (act-064992, actelion-1) Foamix Pharmaceuticals Ltd. Menlo Therapeutics Inc. Hutchison China MediTech Ltd. RegeneRx Biopharmaceuticals Inc. Actelion Ltd. Johnson...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...since its founding in 2017. Bhattacherjee was general manager for the U.K. and Ireland at Actelion Ltd....
BioCentury | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

...the option to license vamorolone from ReveraGen via a sublicense when it spun out of Actelion Ltd....
BioCentury | Jul 27, 2019
Product Development

How Gilead deal positions Galapagos to become Europe’s next big biotech

...Actelion Ltd. when the Swiss biotech was acquired in 2017 by J&J for about $30 billion. Actelion’s...
...argued that remaining independent would create more value than selling the company outright. In 2011, Actelion...
BioCentury | Jul 25, 2019
Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

...most secondary endpoints. Johnson & Johnson gained ponesimod in its 2017 acquisition of Actelion Ltd. (see "Actelion...
BioCentury | Jun 26, 2019
Product Development

AbbVie chooses revenue over innovation with Allergan takeout

...model is the 2017 bolt-on deal by Johnson & Johnson (NYSE:JNJ) in which it acquired Actelion Ltd....
Items per page:
1 - 10 of 1214
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

...Micklus, Senior Biopharma Analyst AbbVie Inc. Allergan plc Takeda Pharmaceutical Co. Ltd. Shire plc Bristol Myers Squibb Co. Celgene Corp. Johnson & Johnson Actelion Ltd. Gilead...
BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

...too, is a veteran of the rare metabolic disease space, having worked on programs at Actelion Ltd....
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...company Arvelle Therapeutics GmbH appointed Otto Schwarz as chairman. He was EVP and COO of Actelion Ltd....
BioCentury | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

...arterial hypertension (PAH) drugs that Johnson & Johnson (NYSE:JNJ) gained through its 2017 acquisition of Actelion Ltd....
BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

...a mAb fragment that binds VEGF and neutralizes it. Actelion pulls regulatory submissions for Opsumit Actelion Ltd....
...data will be needed to evaluate an sNDA for the endothelin receptor antagonist in CTEPH. Actelion...
...foam (FMX103) Elunate, fruquintinib (HMPL-013) RGX-314 Opsumit, macitentan (act-064992, actelion-1) Foamix Pharmaceuticals Ltd. Menlo Therapeutics Inc. Hutchison China MediTech Ltd. RegeneRx Biopharmaceuticals Inc. Actelion Ltd. Johnson...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...since its founding in 2017. Bhattacherjee was general manager for the U.K. and Ireland at Actelion Ltd....
BioCentury | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

...the option to license vamorolone from ReveraGen via a sublicense when it spun out of Actelion Ltd....
BioCentury | Jul 27, 2019
Product Development

How Gilead deal positions Galapagos to become Europe’s next big biotech

...Actelion Ltd. when the Swiss biotech was acquired in 2017 by J&J for about $30 billion. Actelion’s...
...argued that remaining independent would create more value than selling the company outright. In 2011, Actelion...
BioCentury | Jul 25, 2019
Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

...most secondary endpoints. Johnson & Johnson gained ponesimod in its 2017 acquisition of Actelion Ltd. (see "Actelion...
BioCentury | Jun 26, 2019
Product Development

AbbVie chooses revenue over innovation with Allergan takeout

...model is the 2017 bolt-on deal by Johnson & Johnson (NYSE:JNJ) in which it acquired Actelion Ltd....
Items per page:
1 - 10 of 1214